Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $633.1 million.

  • Amicus Therapeutics' Total Non-Current Liabilities rose 653.49% to $633.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $633.1 million, marking a year-over-year increase of 653.49%. This contributed to the annual value of $583.9 million for FY2024, which is 339.71% down from last year.
  • Per Amicus Therapeutics' latest filing, its Total Non-Current Liabilities stood at $633.1 million for Q3 2025, which was up 653.49% from $602.4 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Total Non-Current Liabilities ranged from a high of $633.1 million in Q3 2025 and a low of $532.8 million during Q1 2021
  • For the 5-year period, Amicus Therapeutics' Total Non-Current Liabilities averaged around $588.2 million, with its median value being $587.8 million (2025).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 7258.54% in 2021, then crashed by 444.29% in 2024.
  • Amicus Therapeutics' Total Non-Current Liabilities (Quarter) stood at $577.4 million in 2021, then rose by 0.39% to $579.7 million in 2022, then increased by 4.26% to $604.4 million in 2023, then dropped by 3.4% to $583.9 million in 2024, then grew by 8.43% to $633.1 million in 2025.
  • Its last three reported values are $633.1 million in Q3 2025, $602.4 million for Q2 2025, and $587.8 million during Q1 2025.